What Is TB-500?
TB-500 is a thymosin beta-4 fragment supplied by Peptegrity for research and educational purposes. This page provides a factual educational overview of TB-500, including its classification, biological target, research background, terminology and published study context. It is not a product page and does not provide dosing instructions, treatment recommendations or personal-use guidance.
Type of compound
TB-500 is a synthetic version of the active fragment of the naturally occurring protein thymosin beta-4, specifically referring to the 17-23 amino acid sequence. It is classified as an actin-sequestering peptide.
Biological target and mechanism
The primary mechanism of action involves the modulation of actin polymerization, which is essential for cell motility and structural integrity [1]. By interacting with actin, the peptide is studied for its role in cellular signaling pathways that support tissue repair and angiogenesis [1][3].
Research background
Research into thymosin beta-4 and its fragments began with the exploration of its presence in various tissues and its role in physiological homeostasis [4]. Scientists investigate this compound to understand its potential effects on cellular migration, wound healing, and regeneration in various research models [3][4].
Current research and development status
TB-500 is currently an investigational research compound and is not an approved medication for any human use. It is being studied in various laboratory settings and clinical trials to determine its biological effects [2][5].
Published research context
Published literature investigates the peptide's role in promoting angiogenesis and its pharmacological profile in animal models [1][3]. Recent studies have also evaluated the initial safety and pharmacokinetic characteristics in humans [2], while others explore its potential in regenerative medicine contexts [4][5].
Relevant terminology
Actin-sequestering refers to the peptide's ability to bind to G-actin, preventing it from polymerizing into F-actin filaments, which regulates the cellular cytoskeleton. Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels, a process often studied in relation to tissue repair.
Storage and handling terminology
For research purposes, lyophilized peptides should typically be stored in a cool, dry environment, often at -20°C or -80°C for long-term stability. Once reconstituted in an appropriate buffer, the solution should be kept at refrigerated temperatures and used promptly to maintain structural integrity.
Testing and Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document issued by a laboratory that details the results of quality control testing for a specific batch of a compound. This typically includes purity assessment via HPLC (High-Performance Liquid Chromatography) and identity verification via Mass Spectrometry (MS) [3].
Regulatory status
TB-500 is not approved by the FDA, TGA, or any other regulatory body for human therapeutic or medical use. It is classified as a research chemical intended strictly for laboratory and scientific investigation.
This page is for research and educational purposes only. It is not intended to provide medical advice, dosing instructions, or treatment recommendations, and does not represent any product as approved to diagnose, treat, cure or prevent any disease. Compounds described here may be investigational or unapproved medicines; regulatory status is summarised for information only.
Frequently asked questions
What is TB-500?
TB-500 is a synthetic fragment derived from the protein thymosin beta-4, primarily used in laboratory settings to study actin regulation and cellular responses.
How is TB-500 classified?
It is categorized as an actin-sequestering peptide, known for its interaction with cytoskeletal proteins in biological research models [1].
What is the regulatory status of TB-500?
TB-500 is an investigational compound and is not approved by health authorities for human use or consumption.
What does current research focus on regarding TB-500?
Research focuses on its potential to influence angiogenesis, cellular migration, and its physiological properties in various experimental conditions [1][3][4].
References
- 1.The actin binding site on thymosin beta4 promotes angiogenesisPubMed
- 2.A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteersPubMed
- 3.Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitroPubMed
- 4.Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapiesPubMed
- 5.TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular DiseaseClinicalTrials.gov
